Market revenue in 2023 | USD 134.4 million |
Market revenue in 2030 | USD 242.3 million |
Growth rate | 8.8% (CAGR from 2023 to 2030) |
Largest segment | Transvenous implantable cardioverter-defibrillators |
Fastest growing segment | Subcutaneous Implantable Cardioverter Defibrillators |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Transvenous Implantable Cardioverter-Defibrillators, Subcutaneous Implantable Cardioverter Defibrillators |
Key market players worldwide | Abbott Laboratories, Medtronic PLC, BIOTRONIK, Boston Scientific Corp, MicroPort Scientific Corp, LivaNova PLC |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to implantable cardioverter defibrillators market will help companies and investors design strategic landscapes.
Transvenous implantable cardioverter-defibrillators was the largest segment with a revenue share of 90.55% in 2023. Horizon Databook has segmented the China implantable cardioverter defibrillators market based on transvenous implantable cardioverter-defibrillators, subcutaneous implantable cardioverter defibrillators covering the revenue growth of each sub-segment from 2018 to 2030.
With the rising prevalence of CVDs, the burden in China’s healthcare industry is growing. The research article titled Cardiovascular Disease Mortality and Potential Risk Factor in China published in April 2022, highlighted that cardiovascular disease (CVD) constitutes a significant healthcare burden in China.
The article estimated that approximately 290 million people in China suffer from these conditions. Among them, 13 million individuals are affected by cardiac disorders, 11 million by stroke and coronary heart disease, 2.5 million by rheumatic heart disease, 4.5 million by heart failure, 2 million by congenital heart disease, 5 million by pulmonary heart disease, and 245 million by hypertension.
The same article also states that 40% of the total mortality related to CVD occurs in China alone. This substantial burden and ongoing risk of CVD in China is driving the demand for cardiology medical devices, contributing to market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the China implantable cardioverter defibrillators market , including forecasts for subscribers. This country databook contains high-level insights into China implantable cardioverter defibrillators market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account